

Amendments to the Specification

Please add the following new heading and paragraphs at page 1 after the second full paragraph:

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. illustrates a plot of a number of compounds studied at the National Cancer Institute, versus the hollow fiber score of the compounds.

Figure 2. illustrates the plots of average $-\log LC_{50}$ values versus the cancer type for yujungamycin A(+) and A(-). Each $-\log LC_{50}$ value is the average of up to eight values.


Figure 3. illustrates the results of S(-) and R(+) Yujungamycin A in the B-16 melanoma model in C57/bl mice. These compounds were studied at two dose levels: 1 and 3 mg/Kg IP on days 1, 5, and 9 after tumor implantation into the front flank muscle. Shown in the bar graph is the area under the tumor versus time curve plotted against dose for each enantiomer. Note that there are no apparent differences between the enantiomers in these data.

Figure 4. illustrates the plots of $-\log LC_{50}$ versus cancer type for S (-)-1, 2, 3. Each cancer type represents the average of six to eight different cancer cell lines. The 3-amino derivative **2** shows high cytotoxicity against non-small-cell lung, central nervous system, melanoma, ovarian, and renal cancers.

AMENDMENT IN RESPONSE TO OFFICE ACTION
United States Patent Application No. 09/889,530

Please delete the entire paragraph starting with "SCHEME 2" (consisting of a chemical reaction sequence), and replace it with the following:

SCHEME 2



AMENDMENT IN RESPONSE TO OFFICE ACTION
United States Patent Application No. 09/889,530

Please delete the paragraph (including heading and entire graph) beginning at the first line of page 8.

Please delete the paragraph (including heading and entire graph) beginning at the first line of page 9.

Please delete the paragraph starting with “**Figure 3.** Results of

Please delete the paragraph (including heading and entire graph) beginning at the first line of page 11.